Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Arqit Quantum Inc (ARQQ) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Arqit Quantum IncTrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Arqit Quantum Inc vs Citius Pharmaceuticals Inc — how do they compare? Arqit Quantum Inc trades at $23.52 (market cap $424.79M), while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: Arqit Quantum Inc is far larger — about 21.2× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

ARQQCTXR
Market Cap
$424.79M$20.01M
Sector
TechnologyHealth
52-Week High
$58.27$1.82
52-Week Low
$11.78$0.48
Enterprise Value
$398.10M$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Arqit Quantum Inc

ARQQ trades at $23.70, up 4.82% today, with a bullish technical signal from moving averages and ADX. The stock shows extreme valuation metrics with a P/S of 352.9 and P/B of 14.9, while fundamentals reveal severe losses: Q1 2026 EPS missed at -$1.99, net income margin is -4,508.1%, and revenue remains minimal at $530K for 2025. Recent news highlights a proof of concept with nLighten and 829% YoY revenue growth in H1 FY26, signaling potential commercial traction in quantum-safe encryption.

Outlook hinges on scaling revenue to justify valuation, with risks from persistent cash burn and high SG&A. Analyst sentiment is split 50/50 buy/hold, reflecting optimism for government/telecom contracts against financial distress. The stock faces volatility near resistance at $25, requiring sustained growth to support bullish momentum.

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Arqit Quantum Inc

Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.

Read more on ARQQ

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR